Corona Virus Covid 19

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
DRDO's New Covid Drug 2-DG: All You Need To Know
DRDO's New Covid Drug 2-DG: The DCGI recently granted permission for emergency use of the drug as an adjunct therapy in moderate to severe Covid patients.
All India
Edited by Saikat Kumar Bose
Updated: May 18, 2021 3:02 pm IST


DRDO's New Covid Drug 2-DG: All You Need To Know


DRDO's New Covid Drug 2-DG should also work against various strains of Covid.


New Delhi:
As India battles the second wave of Covid infections, an anti-Covid drug found to help speed up recovery and reduce oxygen dependence has been launched by the government.
The drug, named 2-deoxy-D-glucose (2-DG), has been developed jointly by Institute of Nuclear Medicine and Allied Sciences, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories, Hyderabad.
The Drugs Controller General of India (DCGI) earlier this month granted permission for emergency use of the drug as an adjunct therapy in moderate to severe Covid patients.

How does the drug work?
A government release said it accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. What makes this drug unique is its selective accumulation in the infected cells, the release said.
It should also work against various strains of the Covid virus, DRDO chairperson Dr G Satheesh Reddy has said.

How were the trials conducted?
In April 2020, INMAS-DRDO scientists conducted experiments with the help of Centre for Cellular and Molecular Biology and found that this molecule works effectively against Covid and inhibits viral growth. Based on the results, DGCI's Central Drugs Standard Control Organization permitted Phase-II trials.
In Phase-II trials conducted on 110 patients between May and October 2020, the drug was found to be safe. Covid patients who were administered the drug showed faster symptomatic cure than patients in the standard care group.

The DGCI then permitted Phase-III trials that were conducted on 220 patients between December 2020 and March 2021 at 27 Covid hospitals across several states. The results showed that a significantly higher proportion of patients in the 2DG group improved symptomatically and became free from supplemental oxygen dependence in comparison to those in the standard care group, said the government release. A similar trend was observed in patients aged more than 65 years.

What about the price and availability?
The government release said that being a generic molecule and analogue of glucose, the drug can be easily produced. It is also easy to consume as it comes in a powdered form in a sachet and can be taken orally by dissolving it in water.
Asked about the pricing of the drug, Dr Sudhir Chandna of DRDO has said it will depend on the scale of production. "Those factors are with Dr Reddy's Laboratories who are our industry partners," he was quoted as saying by news agency ANI. He added that efforts are being made to ensure that the drug is available in the market in the next few days.

Where does the drug fit in?
The drug has been launched at a time when the country is battling a devastating second wave of Covid infections that has triggered a race for medical oxygen and hospital beds in most parts of the country. In this situation, a drug found to expedite recovery and reduce oxygen dependence would ensure better availability of beds for patients requiring critical care. At the same time, it would prevent the rampant black marketing of oxygen equipment that has started in the wake of the crisis.

(With inputs from ANI)


DRDO's New Covid Drug 2-DG: All You Need To Know
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
New Covid Drug 2 DG by DRDO launched - How 2 deoxy D glucose medicine fights Covid 19?
7,208 views
•Premiered 5 hours ago


492
19


Study IQ education


9.67M subscribers

New Covid Drug 2DG by DRDO launched - How 2deoxyDglucose medicine fights Covid19? studyiq | study iq | study iq current affairs | May current affairs 2021 2 deoxy D glucose, 2 deoxy d glucose medicine, 2 deoxy d glucose price in india, 2 deoxy d glucose covid 19
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
India gets new Covid medicine, developed by DRDO: How it works, how to use
465,804 views
•May 8, 2021


8.5K
206


Hindustan Times


3.18M subscribers

As India struggles against a devastating wave of Covid-19 infections, authorities cleared a medicine developed by Defence Research & Development Organisation's INMAS (Institute of Nuclear Medicine & Allied Sciences), and pharma major Dr Reddy's Laboratories. The anti-Covid application of 2-deoxy-D-glucose (2-DG) has been found to help in faster recovery of hospitalised patients, and reduce supplemental oxygen dependence, as per clinical trials. Watch the full video for more.
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
DRDO's anti-Coronavirus medicine 2-DG launched, here is what Dr Harsh Vardhan said
23,422 views
•May 17, 2021


442
30


ABP NEWS


29.3M subscribers

The first batch of DRDO-developed anti-Covid drug 2-DG (2-deoxy-D-glucose) was launched on Monday to treat patients suffering from the deadly disease. The medicine comes in powder form and can be taken with water. Defence Minister Rajnath Singh and Health Minister Harsh Vardhan released the first batch of the 2-DG, an anti-Covid-19 therapeutic application of the drug developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO) in collaboration with Dr Reddy's Laboratories (DRL). Rajnath Singh handed over the anti-Covid drug to his cabinet colleague Harsh Vardhan who handed over it to Delhi All India Institute of Medical Sciences (AIIMS) director Randeep Guleria at an event here.
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
‘Plasma therapy dropped from Covid-19 treatment protocol’: ICMR

India on Monday dropped convalescent plasma therapy from the list of treatments prescribed for the management of adult coronavirus disease (Covid-19) patients, a move that triggered growing evidence against the therapy benefiting Covid-19 patients in any way
By Rhythma Kaul

UPDATED ON MAY 18, 2021 01:06 AM IST

India on Monday dropped convalescent plasma therapy from the list of treatments prescribed for the management of adult coronavirus disease (Covid-19) patients, a move that triggered growing evidence against the therapy benefiting Covid-19 patients in any way.

The revised guidelines jointly issued by the Indian Council of Medical Research (ICMR)-Covid-19 National Task Force, All India Institute of Medical Sciences, Delhi, and Union ministry of health and family welfare, do not mention the use of convalescent plasma therapy.
Convalescent plasma therapy uses a blood component called plasma rich in virus-fighting antibodies from recovered Covid-19 patients to aid the immune system in fighting off the infection.
The data from the PLACID trial by the Indian Council of Medical Research (ICMR) that was conducted at 39 centres across India, was released in September last year, found that the therapy did not prevent progression to severe disease or reduce the number of deaths at 28-days of enrolment of the patient.
“ICMR has made it public in the past also that the therapy isn’t of much use based on the evidence that we have, and the earlier revised guidelines were also drastically modified for reference of those wanting to administer it, with clear cut dos and don’ts mentioned under which it can be given. But now it has been deleted from the list of therapies altogether,” said one of the members of the National Task Force, who is aware of the matter, requesting anonymity.

 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
After ICMR revises guidelines on plasma therapy, YCMH stops donor and request helplines
"Since the government has dropped plasma therapy from Covid protocol, we too have stopped Plasma Donor Helpline and Plasma Request Helpline," YCM hospital dean Dr Rajendra Wable told The Indian Express on Tuesday.

Written by Manoj Dattatrye More | Pune |

May 18, 2021 11:59:13 pm




The guidelines had suggested use of plasma therapy when the Covid-19 patient had moderate disease or within seven days of the onset of symptoms.
After the central government on Monday dropped the off-label use of convalescent plasma from the guideline, citing its ineffectiveness, YCM hospital on Tuesday stopped the Plasma Donor Helpline and Plasma Request Helpline. The hospital administration said it will wait for a final order on halting plasma therapy altogether.
“Since the government has dropped plasma therapy from Covid protocol, we too have stopped Plasma Donor Helpline and Plasma Request Helpline,” dean Dr Rajendra Wable told The Indian Express on Tuesday.
Dr Wable said stopping the helplines meant donors will not crowd the hospital, besides there will be no calls requesting plasma bags for Covid-19 patients undergoing treatment at other hospitals.

On Monday, Indian Council of Medical Research (ICMR) said, following a meeting between its officials and the national task force, Clinical Guidance for Management of Adult Covid-19 Patients had been revised and convalescent plasma had been dropped from the guidelines.
The guidelines had suggested use of plasma therapy when the Covid-19 patient had moderate disease or within seven days of the onset of symptoms.
Dr Wable said they will wait for the final communication from the state government regarding plasma therapy. “In the meantime, collection of plasma for other infections will continue. Also, till we receive the final communication, we will leave it to the concerned physician to take a call on plasma therapy. Each physician had a different experience with plasma therapy, so we will leave it to them. If they want plasma for the patient, we will make it available,” he said.
Prof Pravin Soni, incharge of department of medicine, YCMH, said, “After the ICMR decision, we have stopped plasma therapy at the hospital. Anyway, plasma therapy was not benefiting Covid patients… I have instructed our doctors not to use plasma therapy on Covid patients.”
Dr Aniket Lathi, one of the doctors looking after plasma therapy at YCMH, said, “Plasma therapy seems to have been dropped after it was observed that virulent strain developed after its irrational use.” He added that ICMR has said plasma therapy did not offer any benefit to patients when the disease was progressing to a severe form.
Dr Shankar Mosalgi, who heads YCMH blood bank that collects plasma from patients who have recovered from Covid-19, said, “We will wait for FDA (Food and Drug Administration) guidelines in this connection. So far, we have not received any communication from the government…”
When contacted, FDA joint commissioner S B Patil said, “I am aware of the decision by the government. We are also waiting for communication from the government. As soon as we receive it, we will disseminate information to hospitals and blood banks.”
Dr Mosalgi said in the last one year, they had provided plasma to 3,000 patients. “This number is both civic hospital patients as well as those from other hospitals in Pimpri-Chinchwad,” he said.
Dr Mosalgi added that their observation was that plasma therapy was being used irrationally. “Some private hospital doctors recommended plasma when other options had failed. Actually, two plasma bags for one patient is the norm. But some doctors demanded more than two. I know about one prominent personality, for whom five bags were collected from YCMH. This only reflected the irrational use of plasma,” he said.
Dr Mosalgi also said a few days ago, 20 to 22 people were turning up to donate plasma. “The number had come down to less than 10 recently,” he said, adding that the PCMC had promised Rs 2,000 per donation.

He said they had not been able to keep track of the number of patients that benefited from plasma therapy.


After ICMR revises guidelines on plasma therapy, YCMH stops donor and request helplines
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
Plasma therapy can be used in moderate Covid cases, says IMA after new govt guidelines
The govt has revised the clinical guidance for Covid treatment, dropping the off-label use of convalescent plasma as it was not found beneficial.
ANI 18 May, 2021 4:59 pm IST


A recovered Covid-19 patient donates plasma at Delhi's new plasma bank, located at the Institute of Liver & Biliary Sciences, Thursday | Suraj Singh Bisht | ThePrint


A recovered Covid-19 patient donates plasma at Delhi's new plasma bank, located at the Institute of Liver & Biliary Sciences, Thursday | Suraj Singh Bisht | ThePrint


New Delhi: Indian Medical Association (IMA) on Tuesday lent its support to plasma therapy in moderate cases of COVID-19 infection and said such patients may need less oxygen with the use of plasma.
The approval for plasma therapy from the IMA comes a day after Indian Council of Medical Research (ICMR)’s National Task Force (NTF) had dropped use of convalescent plasma therapy from COVID-19 treatment protocol. “What the IMA is saying is that it (plasma therapy) has been removed as an ‘off label’ use. But it is a clinical step that in moderate cases where oxygen saturation is low, the patient may need less oxygen to stabilise or saturate the oxygen level with the use of plasma,” Dr Anil Goel, finance secretary IMA and urologist, told ANI.


“The use of plasma is being put to use with the consent of patients and attendants,” Dr Goel added.
He further said that the high death rate is because the patients are going to hospitals very late, especially those who are in home quarantine.
“I advise them to see a chest specialist at some COVID hospital regularly for their better and early treatment,” Dr Goel added.

On Monday, the use of convalescent plasma was dropped from the recommended treatment protocols for COVID-19.
On May 14, a meeting of the ICMR-National Task Force for Covid-19 was held during which its ‘ineffectiveness’ in a number of cases was discussed.


Plasma therapy can be used in moderate Covid cases, says IMA after new govt guidelines
 

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
COVID Treatment Guidelines: ICMR Drops Plasma Therapy From Clinical Mgmt | Coronavirus Pandemic
1,033 views
•May 18, 2021


9
3


CNBC-TV18


768K subscribers

ICMR drops plasma therapy from COVID-19 treatment protocol. Dr Rahul Pandit Member of SC National Task Force & Director - Critical Care at Fortis Hospital (Mumbai), Dr Priya Sampathkumar, Infectious Diseases Expert at Mayo Clinic, USA & Dr Vishal Rao, Member - Expert Committee of Karnataka COVID Task Force on the #COVID19 battle, rural spread, treatment protocols, vaccination & more
 
Last edited:

adsatinder

Plz Help Himabuj (Amit Tyagi) in Corona Fighting
After ICMR drops plasma therapy from guidelines, IMA clarifies usage in Covid
1,453 views
•May 18, 2021


27
2


Hindustan Times


3.18M subscribers

Indian Medical Association (IMA) on Tuesday lent its support to plasma therapy in moderate cases of COVID-19 infection and said such patients may need less oxygen with the use of plasma. "What the IMA is saying is that it (plasma therapy) has been removed as an 'off label' use. But it is a clinical step that in moderate cases where oxygen saturation is low, the patient may need less oxygen to stabilise or saturate the oxygen level with the use of plasma," Dr Anil Goel, finance secretary IMA said. Watch the full video for more details.
 
Top